DALLAS, March 17, 2021 /PRNewswire/ -- Lantern Pharma
Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company
using its proprietary RADR® artificial intelligence
("A.I.") platform to transform oncology drug discovery and
development today announced that it has filed seven patent
applications globally on a novel DNA-damaging agent with anticancer
properties. These patent applications include claims directed to a
newly synthesized compound with promising in-vitro
anticancer activity in a range of indications that are distinct
from LP-184. This compound, newly designated as LP-284,
is believed to act through mechanisms that are related to
DNA-damage and DNA-repair inhibition in certain cancer cells.
![Lantern Pharma (LTRN) Logo (PRNewsfoto/Lantern Pharma) Lantern Pharma (LTRN) Logo (PRNewsfoto/Lantern Pharma)](https://mma.prnewswire.com/media/1216507/Lantern_Pharma_Logo.jpg)
LP-284 is a small molecule drug candidate currently in
preclinical development for certain cancers that have shown
sensitivity to the compound. LP-284 is the
stereoisomer (enantiomer) of LP-184 and has the potential for
development as monotherapy and also as a synergistic agent in
combination with other drugs. Stereoisomers can have differing and
unique characteristics from one another and can be viewed as
distinct pharmaceutical agents. These unique characteristics may
allow LP-284 to also be considered for inclusion in Lantern
Pharma's antibody drug conjugate (ADC) program.
The individual stereoisomers of a biologically active molecule
may often differ in potency, pharmacological action, metabolism,
toxicity, and kinetics. This phenomenon applies to chiral
anticancer agents such as LP-184 and LP-284. The enantiomers, which
are different molecules, possess distinct cancer cell-killing
activity. Due to these differences, we can expand the range of
potential cancer indications that can be addressed by the Lantern
portfolio. These differences can be better understood though the
use of data-driven methodologies, such as large-scale genomic
analysis and in-silico studies. Lantern expects to apply
these insights to develop LP-284 in cancer indications that are
different and complementary to those being targeted by LP-184.
"The insights and developments from our team are rapidly leading
to new therapy opportunities in a targeted and cost-effective
manner. The designation of LP-284 as a new drug candidate
demonstrates our continued ability to efficiently advance and
expand Lantern's portfolio of targeted therapies," stated
Panna Sharma, CEO & President of
Lantern Pharma.
LP-284 will be advanced using Lantern's proprietary
RADR® A.I. platform that leverages over 1.2 billion data
points, machine learning, genomics, and computational biology to
accelerate the discovery of potential mechanisms of action, and
biomarker signatures that correlate to drug response in cancers and
in cancer patients.
Based on Lantern's previously filed PCT ("Patent Cooperation
Treaty") patent application, Lantern has filed national stage
patent applications to seek protection for LP-284 in major market
countries throughout the world. The national stage patent
applications allow, if granted, for patent protection of
LP-284. The filed, multi-national patent applications are
directed to both the composition and manufacture of LP-284. Lantern
previously licensed patents related to LP-184 from AF Chemicals,
LLC. Lantern has also filed an additional 8 patent applications
that include method and use claims directed to LP-184 in specific
solid tumors and also in combination with other drug compounds in
specific tumors. Lantern's patent applications also include claims
related to the manufacture of LP-184 in a fully synthetic
manner.
"Our patent strategy will continue to be highly focused on
protecting our insights and developmental pathways for our drug
candidates on a global basis. These seven patent applications are
consistent with our focus on becoming a leader in the global
development of precision oncology therapies," said Mr. Sharma of
Lantern Pharma.
About Lantern Pharma
Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical
company leveraging advances in genomics, artificial intelligence,
and machine learning by using our proprietary RADR® A.I.
platform to discover biomarker signatures that identify patients
most likely to respond to our pipeline of cancer therapeutics.
Lantern is currently developing three drug candidates and an ADC
program across seven disclosed targets, including two phase 2
programs, all focused on cancers with unique and unmet clinical
needs. By targeting drugs to patients whose genomic profile
identifies them as having the highest probability of benefiting
from the drug, this approach represents the potential to deliver
best-in-class outcomes. More information at www.lanternpharma.com
and Twitter @lanternpharma.
Contact
Marek Ciszewski, JD
Director, Investor Relations
628-777-3167
ir@lanternpharma.com
Forward-looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other
things, statements relating to: our strategy and plans regarding
our patents and patent applications; future events or our future
financial performance; the potential advantages of our RADR®
platform in identifying drug candidates and patient populations
that are likely to respond to a drug candidate; our strategic plans
to advance the development of our drug candidates and antibody drug
conjugate (ADC) development program; estimates regarding the
development timing for our drug candidates and ADC development
program; our research and development efforts of our internal drug
discovery programs and the utilization of our RADR® platform to
streamline the drug development process; our intention to leverage
artificial intelligence, machine learning and genomic data to
streamline and transform the pace, risk and cost of oncology drug
discovery and development and to identify patient populations that
would likely respond to a drug candidate; estimates regarding
potential markets and potential market sizes; sales estimates for
our drug candidates and our plans to discover and develop drug
candidates and to maximize their commercial potential by advancing
such drug candidates ourselves or in collaboration with others. Any
statements that are not statements of historical fact (including,
without limitation, statements that use words such as "anticipate,"
"believe," "contemplate," "could," "estimate," "expect," "intend,"
"seek," "may," "might," "plan," "potential," "predict," "project,"
"target," "aim," "should," "will," "would," or the negative of
these words or other similar expressions) should be considered
forward-looking statements. There are a number of important factors
that could cause our actual results to differ materially from those
indicated by the forward-looking statements, such as (i) the impact
of the COVID-19 pandemic, (ii) the risk that our patents and patent
applications may not provide the protection we seek; (iii) the risk
that changes to patent laws in the United
States and other jurisdictions could diminish the value of
patents in general; (iv) the risk that none of our product
candidates has received FDA marketing approval, and we may not be
able to successfully initiate, conduct, or conclude clinical
testing for or obtain marketing approval for our product
candidates; (v) the risk that no drug product based on our
proprietary RADR A.I. platform has received FDA marketing approval
or otherwise been incorporated into a commercial product, and (vi)
those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and
Exchange Commission on March 10,
2021. You may access our Annual Report on Form 10-K for the
year ended December 31, 2020 under
the investor SEC filings tab of our website at
www.lanternpharma.com or on the SEC's website at www.sec.gov. Given
these risks and uncertainties, we can give no assurances that our
forward-looking statements will prove to be accurate, or that any
other results or events projected or contemplated by our
forward-looking statements will in fact occur, and we caution
investors not to place undue reliance on these statements. All
forward-looking statements in this press release represent our
judgment as of the date hereof, and, except as otherwise required
by law, we disclaim any obligation to update any forward-looking
statements to conform the statement to actual results or changes in
our expectations.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lantern-pharma-announces-filing-of-seven-patent-applications-globally-on-novel-dna-damaging-agent-with-anticancer-properties-301249264.html
SOURCE Lantern Pharma